We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


MedMira Expands Multiplo Product Range with Three New Rapid Vertical Flow Tests

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "MedMira Expands Multiplo Product Range with Three New Rapid Vertical Flow Tests"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The new tests being added to the product range include Multiplo TP/nTP, which detects both active and historic syphilis infections, Multiplo TP/HIV/nTP, and Multiplo TP/HIV/HCV, which simultaneously detects syphilis, HIV and hepatitis C. 

The full Multiplo line is now available in international markets with analysis of highly regulated markets, possibly including North America and Europe, underway. MedMira will showcase its full Multiplo line for the first time at the 2014 American Association for Clinical Chemistry (AACC) Annual Meeting & Clinical Lab Expo.

The new tests all deliver instant results for syphilis infection, a disease with an increasing global prevalence rate. Multiplo TP/nTP and Multiplo TP/HIV/nTP take testing a step further, providing comprehensive screening and confirmatory results for both present and past syphilis infections.  Detecting the presence of both current and previous infections provides critical information to help healthcare providers in determining the right course of treatment for their patients.  

“The creativity and innovation powered by our patented RVF Technology is limitless and this expansion of our Multiplo product range is a prime example of how the technology enables new rapid tests to fast track through discovery, design, and development to meet customer demands,” said Dr. Kevin Jones, Senior Director Sales & Marketing, MedMira.  “The WHO has identified syphilis as a serious global healthcare issue and our Multiplo tests will prove invaluable in large scale testing programs targeting multiple diseases, especially prenatal maternal initiatives.  Multiplo TP/HIV is currently under evaluation as part of the WHO prequalification program and we look forward to working with them to bring our newest Multiplo tests to screening programs around the world.”

The World Health Organization (WHO) estimates that there are more than 12 million new cases of adult syphilis each year, with an additional 500,000 cases affecting infants through maternal transmission.  It is the mission of WHO, and many other healthcare initiatives, to decrease transmission of HIV and syphilis from mothers to their children.  With prenatal diagnosis using Multiplo rapid tests, at risk pregnancies can be identified within two minutes, greatly reducing the risk of mother-to-child HIV and syphilis transmission.